Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1A4BS)

Drug Name

2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole Drug Info

Synonyms

CHEMBL276868; 67277-66-1; 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole; SCHEMBL8229695; CTK1J3678; DTXSID50658095; ZINC13806045; BDBM50151704; AKOS022538449; 2-(4-tert-Butylphenyl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-[4-(1,1-dimethylethyl)phenyl]-4,5-dihydro-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 44269078
CAS Number: CAS 67277-66-1
TTD Drug ID: DM1A4BS

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
Eletriptan	DMW649X	Migraine	8A80	Approved	[3]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[3]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[3]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[4]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[5]
Almogran	DM7I64Z	Migraine	8A80	Approved	[6]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[7]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[8]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[10]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[10]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[3]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[11]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[12]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[13]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[14]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[15]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[15]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9.
2	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
5	An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
6	Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
7	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Company report (NeurAxon)
10	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
11	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
12	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
13	Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
14	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
15	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
16	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.